{"id":"NCT05683340","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia","officialTitle":"A Placebo-controlled, Randomized, Multicenter, Double-blind, Parallel-group Trial to Confirm the Superiority of ETC-1002 in Patients With Hyper-LDL Cholesterolemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-02-13","primaryCompletion":"2024-02-20","completion":"2024-03-12","firstPosted":"2023-01-13","resultsPosted":"2025-03-13","lastUpdate":"2025-03-13"},"enrollment":96,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyper-low-density Lipoprotein (LDL) Cholesterolemia"],"interventions":[{"type":"DRUG","name":"180mg of ETC-1002(bempedoic acid)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"ETC-1002 180mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to confirm the superiority of ETC-1002 after 12 weeks of administration at 180 mg/day to placebo in patients with hyper-LDL cholesterolemia who have inadequate control of low-density lipoprotein cholesterol (LDL C).","primaryOutcome":{"measure":"Percent Change in LDL-C From Baseline to Week 12","timeFrame":"Baseline, week12","effectByArm":[{"arm":"ETC-1002 180 mg","deltaMin":-25.25,"sd":1.864},{"arm":"Placebo","deltaMin":-3.46,"sd":1.901}],"pValues":[{"comp":"OG000 vs OG001","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":11},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":48},"commonTop":["Nasopharyngitis","Back pain","Arthralgia"]}}